Pfizer Inc. is demonstrating once again how expensive it is for pharma firms to buy their way to growth. The company announced that it’s paying almost $11 billion for cancer drugmaker Array Biopharma Inc. The deal would bolster Pfizer’s cancer portfolio and add medicines that could meaningfully augment sales and profit. But the company isn’t getting much of a bargain, ...

Boeing Co. just got a big vote of confidence, but it still has much to prove. The commercial-jet maker announced a surprise order for its 737 Max jet – the first since the top-selling aircraft was involved in two fatal crashes that prompted regulators around the globe to ground it and sparked a full-blown crisis for the company. British Airways ...

China’s central bank has acknowledged its monetary tools are insufficient. The most powerful ones are proving too blunt to drill through a hardening financial system. The country’s money markets have been shuddering since regulators took over Baoshang Bank Co. last month, despite initial assurances from the central bank and other authorities that they would maintain ample liquidity. While there has ...